Each of the three commentaries on our article1 raises important issues for discussion.Lee and Tobin2 claim a discrepancy between our findings of reduced glutamic acid decarboxylase messenger RNA (GAD mRNA) levels in the prefrontal cortex of schizophrenics and the lack of similar changes in GAD enzyme activity reported by Hanada et al.3 This is not surprising, given the fact that GAD enzyme is unstable and its activity is influenced by confounding factors such as autolysis time4 and cause of death.3,5 Two other studies reported decreased GAD activity in schizophrenics,6,7 but one only found decreased GAD activity in schizophrenics who did not die a sudden death.5 The GAD mRNA is far more resistant to autolysis, and localization by in situ hybridization was successful in all patients and controls included in this study. In the same specimens, staining of GAD enzyme by means
Akbarian S, Jones EG. In Pursuit of the Molecular Neuropathology of Schizophrenia-Reply. Arch Gen Psychiatry. 1995;52(4):277–278. doi:10.1001/archpsyc.1995.03950160027006
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.